

Yi Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3327746/publications.pdf>

Version: 2024-02-01

107
papers

4,297
citations

186265

28
h-index

118850

62
g-index

118
all docs

118
docs citations

118
times ranked

6053
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau and A β 2 imaging, CSF measures, and cognition in Alzheimer's disease. <i>Science Translational Medicine</i> , 2016, 8, 338ra66.	12.4	560
2	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
3	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	7.1	309
4	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β 2-Amyloid and Tauopathy. <i>JAMA Neurology</i> , 2016, 73, 1070.	9.0	246
5	Loss of Brain Aerobic Glycolysis in Normal Human Aging. <i>Cell Metabolism</i> , 2017, 26, 353-360.e3.	16.2	228
6	Quantitative Analysis of PiB-PET with FreeSurfer ROIs. <i>PLoS ONE</i> , 2013, 8, e73377.	2.5	192
7	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , 2015, 107, 55-64.	4.2	188
8	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. <i>Brain</i> , 2016, 139, 2249-2260.	7.6	150
9	Persistent metabolic youth in the aging female brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3251-3255.	7.1	133
10	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	7.6	122
11	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. <i>NeuroImage</i> , 2017, 161, 171-178.	4.2	116
12	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ϵ 4 genotype. <i>Brain</i> , 2018, 141, 1828-1839.	7.6	99
13	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 513-521.	10.2	97
14	Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart. <i>Circulation Research</i> , 2019, 124, 881-890.	4.5	94
15	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
16	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> , 2016, 80, 379-387.	5.3	82
17	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. <i>Neurobiology of Aging</i> , 2016, 44, 1-8.	3.1	80
18	MR-based attenuation correction for PET/MRI neurological studies with continuous-valued attenuation coefficients for bone through a conversion from R2* to CT-Hounsfield units. <i>NeuroImage</i> , 2015, 112, 160-168.	4.2	79

#	ARTICLE	IF	CITATIONS
19	Longitudinal $\text{A}\beta$ -Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non- $\text{A}\beta$ Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2016, 73, 1192.	9.0	77
20	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018, 19, 406-416.	2.7	76
21	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 67, 95-98.	3.1	73
22	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. <i>Neurology</i> , 2018, 91, e313-e318.	1.1	68
23	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid $\text{A}\beta$ positron emission tomography pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 245-252.	2.4	49
24	Noninvasive Estimation of the Arterial Input Function in Positron Emission Tomography Imaging of Cerebral Blood Flow. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 115-121.	4.3	45
25	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	2.5	45
26	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 177-185.	3.1	42
27	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101767.	2.7	41
28	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. <i>PLoS ONE</i> , 2015, 10, e0122920.	2.5	30
29	Impact of MR-Based Attenuation Correction on Neurologic PET Studies. <i>Journal of Nuclear Medicine</i> , 2016, 57, 913-917.	5.0	28
30	The application of maximum likelihood factor analysis (MLFA) with uniqueness constraints on dynamic cardiac microPET data. <i>Physics in Medicine and Biology</i> , 2007, 52, 2313-2334.	3.0	27
31	Self-Sterilizing and Regeneratable Microchip for the Precise Capture and Recovery of Viable Circulating Tumor Cells from Patients with Cancer. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 207-218.	8.0	27
32	Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. <i>Disease Markers</i> , 2015, 2015, 1-11.	1.3	25
33	Kinetic modeling of [^{18}F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain. <i>Journal of Neurochemistry</i> , 2018, 144, 791-804.	3.9	21
34	Association between personality and tau-PET binding in cognitively normal older adults. <i>Brain Imaging and Behavior</i> , 2020, 14, 2122-2131.	2.1	21
35	Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2648-2654.	3.0	19
36	Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1435-1446.	4.3	19

#	ARTICLE	IF	CITATIONS
37	Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , 2016, 2016, 12.	1.4	18
38	Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline. <i>NeuroImage: Clinical</i> , 2020, 27, 102338.	2.7	18
39	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
40	Attenuation Effects of MR Headphones During Brain PET/MR Studies. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 93-100.	0.8	16
41	Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject. <i>NeuroImage</i> , 2015, 121, 253-262.	4.2	16
42	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
43	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	16
44	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 104-111.	3.1	15
45	Cumulative and Incremental Value of Sarcopenia Components on Predicting Adverse Outcomes. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1481-1489.e3.	2.5	15
46	Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial. <i>Alzheimer's and Dementia</i> , 2020, 16, 1023-1030.	0.8	15
47	Comparing amyloid- β^2 plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
48	The Associations of Dietary Inflammatory Potential With Musculoskeletal Health in Chinese Community-Dwelling Older People: The Mr. OS and Ms. OS (Hong Kong) Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1179-1187.	2.8	15
49	Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAcHt in nonhuman primates. <i>Nuclear Medicine and Biology</i> , 2016, 43, 131-139.	0.6	13
50	Quantitative positron emission tomography reveals regional differences in aerobic glycolysis within the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2096-2102.	4.3	13
51	Single-Input Dual-Output Modeling of Image-Based Input Function Estimation. <i>Molecular Imaging and Biology</i> , 2010, 12, 286-294.	2.6	12
52	Quantifying the Effect of Financial Burden on Health-Related Quality of Life among Patients with Non-Hodgkin's Lymphomas. <i>Cancers</i> , 2020, 12, 3325.	3.7	11
53	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. <i>Medical Image Analysis</i> , 2021, 67, 101877.	11.6	10
54	Wavelet denoising in voxel-based parametric estimation of small animal PET images: a systematic evaluation of spatial constraints and noise reduction algorithms. <i>Physics in Medicine and Biology</i> , 2008, 53, 5899-5915.	3.0	9

#	ARTICLE	IF	CITATIONS
55	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 31, 102749.	2.7	8
56	Preparation and characterization of DNA aptamers against roxithromycin. <i>Analytica Chimica Acta</i> , 2021, 1164, 338509.	5.4	7
57	Fine-tuning the cutpoint T-score as an epidemiological index with high specificity for osteoporosis: methodological considerations for the Chinese population. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 882-885.	2.0	7
58	A neural network to pulmonary embolism aided diagnosis with a feature selection approach. , 2010, , .		5
59	MRI based attenuation correction for PET/MRI via MRF segmentation and sparse regression estimated CT. , 2014, , .		5
60	Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology. <i>Frontiers in Neuroscience</i> , 2021, 15, 762458.	2.8	5
61	The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VChT in the brain of nonhuman primates. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105152.	4.0	4
62	miR-330 regulates interleukin-13-induced MUC5AC secretion by targeting Munc18b in human bronchial epithelial cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 3463-3470.	0.5	3
63	Inter-frame motion correction for small animal PET imaging. , 2011, , .		2
64	IC-01-03: Classifying TAU Pet Positivity With [18F]AV-1451 in Preclinical Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P2.	0.8	2
65	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
66	IC-P-100: The ILP: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P68-P68.		1
67	IC-P-164: Patterns of tau binding in T807-PET imaging. , 2015, 11, P110-P110.		1
68	Investigating the Effect of Tau Deposition and Apoe on Hippocampal Morphometry in Alzheimer's Disease: A Federated Chow Test Model. , 2022, , .		1
69	Single input multiple output (SIMO) optimization for input function estimation: a simulation study. , 2007, , .		0
70	IC-O2-01: How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations. , 2013, 9, P6-P6.		0
71	IC-P-008: REGIONAL PIB DEPOSITION AND CSF A β 42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P11-P11.		0
72	O2-05-04: REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P173-P173.		0

#	ARTICLE	IF	CITATIONS
73	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
74	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
75	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
76	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P697-P697.		0
77	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
78	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
79	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0
80	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
81	O5-06-06: Age-related decreases in tracer influx rate measured with PiB PET. , 2015, 11, P330-P330.		0
82	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
83	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™s Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.8	0
84	P3â€234: Similarities and Differences in Patterns of [F18]â€Avâ€1451 and [F18]â€FDG in Frontotemporal Dementia, Alzheimer's and Dementia, 2016, 12, P915.	0.8	0
85	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
86	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
87	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
88	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
89	[P2â€372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
90	[P1â€008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€Avâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.8	0

#	ARTICLE	IF	CITATIONS
91	[P2â€“374]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P769.	0.8	0
92	[ICâ€“Pâ€“054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
93	[ICâ€“Pâ€“061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.8	0
94	[ICâ€“Pâ€“064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0
95	[ICâ€“Pâ€“138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P105.	0.8	0
96	[ICâ€“Pâ€“166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
97	[ICâ€“Pâ€“205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€“AVâ€“1451 PET. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
98	[ICâ€“02â€“02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€“AVâ€“1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P4.	0.8	0
99	[P1â€“402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.8	0
100	[P1â€“422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€“AVâ€“1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P440.	0.8	0
101	[P2â€“345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.8	0
102	[O1â€“02â€“01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P184.	0.8	0
103	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
104	[O3â€“09â€“05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€“AVâ€“1451 PET. Alzheimer's and Dementia, 2017, 13, P922.	0.8	0
105	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
106	ICâ€“Pâ€“009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.8	0
107	ICâ€“02â€“01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0